Mottola Frank 4

What Happened

• Frank Mottola, Senior Vice President and Chief Technical Operations Officer at Supernus Pharmaceuticals (SUPN), was granted a total of 16,500 derivative awards on February 18, 2026 (13,500 and 3,000 shares). Each award is shown at $0.00 (no cash paid at grant). These awards are equity-based and will vest over time rather than being an open-market purchase or sale.

Key Details

• Transaction date: February 18, 2026; filing date: February 20, 2026.
• Grants: 13,500 and 3,000 derivative awards; aggregate 16,500 awards; reported grant price $0.00 (no immediate cash outlay).
• Vesting: Footnotes indicate these are restricted stock units (each represents the right to one share) and/or awards that vest in four equal annual installments beginning February 18, 2027, and are settled in common stock upon vesting.
• Other ownership note: Filing footnote reports 228 shares acquired through the issuer’s Employee Stock Purchase Plan.
• Shares owned after transaction: Not specified in this Form 4.
• Filing timeliness: Filed Feb 20, 2026 reporting Feb 18, 2026 grants; no late filing indicated.

Context

• These are grants of equity awards (derivative securities), meaning Mottola will receive actual shares only as the awards vest in future installments. Such awards are common for executive compensation and do not reflect an immediate open-market purchase or sale.